Mechanisms, Prevention and Treatment of Chronic Graft-vs.-Host Disease

慢性移植物抗宿主病的机制、预防和治疗

• 批准号: 8933228
• 负责人: Corey S Cutler
• 金额: $ 168.55万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-15 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8933228
• 关键词: Acute Graft Versus Host Disease; Address; Adrenal Cortex Hormones; Allogenic; Antibodies; Antibody Formation; Antigens; B-Cell Activation; B-Lymphocyte Subsets; B-Lymphocytes; Biological; Biological Markers; CSF1R gene; Cell Therapy; Cell physiology; Cellular biology; Chronic; Clinical Research; Clinical Trials; Collagen; Complex; Deposition; Development; Disease; Dose; Elements; Enrollment; Fibrosis; Functional disorder; Future; Goals; Health; Helper-Inducer T-Lymphocyte; Immunoglobulin G; Immunologics; Incidence; Injury; Interleukin-2; Laboratory Study; Lead; Membrane; Modeling; Monitor; Multi-Institutional Clinical Trial; Mus; Newly Diagnosed; Organ; Outcome; Patients; Peptides; Pharmaceutical Preparations; Phase; Plasma Cells; Play; Pre-Clinical Model; Prevention; Prophylactic treatment; Research Design; Role; Safety; Series; Signal Pathway; Signal Transduction; Staging; Structure of germinal center of lymph node; Surface; T cell response; Testing; Therapeutic; Therapeutic Agents; Tissues; Transforming Growth Factor beta; Viral; Work; base; chronic graft versus host disease; clinical effect; clinical efficacy; disorder prevention; graft vs leukemia effect; hematopoietic cell transplantation; improved; in vivo; macrophage; monocyte; mortality; mouse model; nanoparticle; novel; novel therapeutics; peptide V; post intervention; pre-clinical; preclinical study; prevent; programs; response; rituximab; transcription factor

DESCRIPTION (provided by applicant): Chronic GVHD (cGVHD) is the most important adverse long-term consequence of allogeneic hematopoietic cell transplantation (HCT) and represents the most frequent cause of mortality occurring after 1-2 years from HCT. In previous studies supported by this Program Project, we made the novel observation that donor B cells played a critical role in the pathophysiology of cGVHD. This was demonstrated in patients with cGVHD as well as in murine models and this led us to undertake a series of clinical trials that demonstrated the clinical efficacy of B cell-directed therapy in the treatment and prevention of cGVHD. The overarching goal of this Program Project in this renewal is to identify optimal strategies for the application of B cell-directed therapies for the treatment and prevention of cGVHD. In this collaborative effort, we incorporate novel pivotal multi-center clinical trials, preclinical models of cGVHD to identify more effective B cell targeting strategies for future clinical studies and detailed analysis of patients receiving novel therapies. This is a highly integrated Program Project where the new clinical trials in Project 1 have been informed by previous pre-clinical murine studies in Project 2 and laboratory studies demonstrating the role of B cells in patients with cGVHD in Project 3. Project 1, Targeting B Cells in Chronic Graft-versus-Host Disease Prevention and Treatment, is dedicated to clinical trials of anti-B cell therapy that address the unmet need during three phases of cGVHD: pre-clinical presentation, initial therapy and late stage disease. These trials are the next phase of studies leading from our prior work, and are informed by the preclinical studies of Project 2. Project 2, Preclinical Drug Approaches to Chronic GVHD Prevention and Treatment is dedicated to the identification and testing of new drug and peptide therapies of cGVHD in a robust mouse model of cGVHD associated with fibrosis. Project 3, Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host Disease is dedicated to understanding the immunologic effects of B cell-directed therapies in patients treated on clinical trials in Project 1, and potential mechanisms by which these new treatments alter B cell function in vivo. Novel discovery in Project 3 may lead to new biomarkers of cGVHD. Supported by unique and highly integrated cores, we have the opportunity to build on our previous discoveries and improve outcomes for patients with cGVHD.

描述（由申请方提供）：慢性GVHD（cGVHD）是同种异体造血细胞移植（HCT）最重要的长期不良后果，是HCT后1-2年发生的最常见死亡原因。在本项目支持的先前研究中，我们发现供体B细胞在cGVHD的病理生理学中起关键作用。这在cGVHD患者以及鼠模型中得到证实，这使我们进行了一系列临床试验，证明了B细胞导向疗法在治疗和预防cGVHD中的临床疗效。本次更新中该计划项目的总体目标是确定应用B细胞导向疗法治疗和预防cGVHD的最佳策略。在这项合作努力中，我们结合了新的关键多中心临床试验，cGVHD的临床前模型，以确定更有效的B细胞靶向策略，用于未来的临床研究和接受新疗法的患者的详细分析。这是一个高度整合的项目，其中项目1中的新临床试验已通过项目2中先前的临床前小鼠研究和项目3中证明B细胞在cGVHD患者中作用的实验室研究获得信息。项目1，慢性移植物抗宿主病预防和治疗中的靶向B细胞，致力于抗B细胞治疗的临床试验，以解决cGVHD三个阶段未满足的需求：临床前表现，初始治疗和晚期疾病。这些试验是我们先前工作的下一阶段研究，并由项目2的临床前研究提供信息。项目2，慢性GVHD预防和治疗的临床前药物方法致力于在与纤维化相关的cGVHD的稳健小鼠模型中鉴定和测试cGVHD的新药和肽疗法。项目3，慢性移植物与非移植物的体液靶点和B细胞生物学宿主疾病致力于了解B细胞导向疗法在项目1临床试验中治疗的患者中的免疫学效应，以及这些新疗法在体内改变B细胞功能的潜在机制。项目3中的新发现可能导致新的cGVHD生物标志物。在独特和高度集成的核心的支持下，我们有机会建立在我们以前的发现基础上，改善cGVHD患者的预后。